AstraZeneca PLC (AZN)vsTenaya Therapeutics Inc (TNYA)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
TNYA
Tenaya Therapeutics Inc
$0.73
-5.70%
HEALTHCARE · Cap: $171.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 26861677% more annual revenue ($60.44B vs $225,000). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TNYA
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for TNYA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : TNYA
The strongest argument for TNYA centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : TNYA
The primary concerns for TNYA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while TNYA is a value play — different risk/reward profiles.
TNYA carries more volatility with a beta of 2.77 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 25/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Tenaya Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tenaya Therapeutics Inc. is a forward-thinking clinical-stage biotechnology firm dedicated to revolutionizing the treatment landscape for heart disease via its proprietary engineered heart cell platform. With a strong pipeline that features cutting-edge gene therapies and regenerative solutions, Tenaya is well-positioned to address critical unmet needs within cardiovascular medicine, presenting compelling growth prospects in the biopharmaceutical industry. The company's focus on scientific excellence and commitment to improving patient outcomes positions it as a noteworthy investment opportunity for institutional investors keen on fostering advancements in cardiac care and capitalizing on the dynamic cardiovascular therapy market.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?